Related Experiment Video
Updated: Jun 18, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network in human lung cancer cells
1The Ohio State University College of Medicine and Public Health, Columbus, OH, USA. wenrui.duan@osumc.edu
Abstract:
Restoration of p53 function in tumor cells would be an attractive strategy for lung cancer therapy because p53 mutations are found in more than 50% of lung cancers. The small molecule PRIMA-1 has been shown to restore the tumor suppression function of p53 and to induce apoptosis in human tumor cells. The mechanism of apoptosis induced by PRIMA-1 remains unclear. We investigated the effects of PRIMA-1 in apoptosis with Western immunoblot analysis, TaqMan microRNA real-time PCR, cell viability analysis and flow cytometry using human lung cancer cell lines containing mutant (H211 and H1155), wild-type (A549) or null (H1299) p53. PRIMA-1 induced massive apoptosis in the H211 and H1155 cells, but was less toxic to the A549 and H1299 cells. Western immunoblot analysis showed cleavage of PARP in H211 and H1155 cells but not in A549 and H1299 cells following treatment with PRIMA-1. In addition, p53 protein was also phosphorylated in H211 and H1155 cells. TaqMan microRNA assay showed that the expression of microRNA-34a was increased in the H211 and H1155 cells posttreatment. Knockdown microRNA-34a decreased the rate of apoptosis caused by PRIMA-1. The above results suggest that microRNA-34a is one of the important components of PRIMA-1-induced apoptotic network in the cancer cells harboring mutant p53.
Insights
The small molecule PRIMA-1 induces apoptosis in lung cancer cells with mutant p53 by activating microRNA-34a. This finding offers a new therapeutic strategy for lung cancer by restoring tumor suppressor function.
Area of Science:
- Molecular Biology
- Cancer Research
- Pharmacology
Background:
- Over 50% of lung cancers harbor p53 mutations, making p53 restoration a key therapeutic target.
- The small molecule PRIMA-1 can restore p53 tumor suppressor function and induce apoptosis in cancer cells.
- The precise mechanism of PRIMA-1-induced apoptosis is not fully understood.
Purpose of the Study:
- To investigate the mechanism of apoptosis induced by PRIMA-1 in human lung cancer cell lines.
- To determine the role of p53 status in PRIMA-1's apoptotic effects.
- To elucidate the involvement of microRNA-34a in PRIMA-1-mediated apoptosis.
Main Methods:
- Utilized Western immunoblot analysis, TaqMan microRNA real-time PCR, cell viability assays, and flow cytometry.
- Tested PRIMA-1 effects on lung cancer cell lines with mutant, wild-type, and null p53.
- Performed microRNA-34a knockdown experiments to assess its role in apoptosis.
Main Results:
- PRIMA-1 induced significant apoptosis in lung cancer cells with mutant p53 (H211, H1155) but showed less toxicity in wild-type (A549) or null (H1299) p53 cells.
- Western blot analysis confirmed PARP cleavage and p53 phosphorylation in PRIMA-1-treated mutant p53 cells.
- PRIMA-1 treatment upregulated microRNA-34a expression, and its knockdown reduced PRIMA-1-induced apoptosis.
Conclusions:
- MicroRNA-34a is a crucial component of the apoptotic pathway activated by PRIMA-1 in lung cancer cells with mutant p53.
- PRIMA-1's efficacy is linked to the presence of mutant p53, suggesting a targeted therapeutic approach.
- These findings highlight microRNA-34a as a potential mediator in PRIMA-1's anti-cancer activity.
Related Concept Videos
MicroRNAs
MicroRNAs
The Intrinsic Apoptotic Pathway
piRNA - Piwi-interacting RNAs
Experimental RNAi
Abnormal Proliferation

